1. In Vivo
  2. >>Innovation

Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights

 
• By Ashley Yeo

The quality of clinical trials and data analysis have come a long way in the past 10 years – and even in the past three, says Christian Hebenstreit of Medidata, the cloud-based platform that supports pharma and medtech companies through clinical studies ahead of their commercial uptake. The buzzwords of the fairly recent past are now being applied as real tools in the clinical trials arena, and look set to transform the sector.

The London arm of Medidata NEXT, the seven-venue awareness event for clinical trials professionals around the globe, is humming with industry players keen to hear how they can use Medidata Solutions Inc.'s Clinical Cloud tool, which combines science and the operation of clinical trials. At the podium, US product development executive Dave Metz is explaining the MEDS (Medidata Enterprise Data Store) element of the offering: the repository of clinical and operational data that are the basis of clinical process decision-making.

Metz's tone is irrepressibly upbeat: Medidata's service offerings to clinical clients are increasing in speed and quality across the industry. And investors are similarly optimistic: the group has something of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

 
• By David Wild

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By Jo Shorthouse

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By David Wild

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

More from In Vivo

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By David Wild

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

Execs On The Move: April 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.